|
Popular Science Magazine Features The Aethlon
Hemopurifier(TM)
SAN DIEGO---March 14, 2006--Aethlon Medical, Inc. (OTCBB: AEMD), a pioneer
in developing therapeutic devices for infectious disease, announced today
that its Hemopurifier(TM) treatment technology is featured in the April
issue of Popular Science Magazine. The internationally recognized scientific
magazine profiles the potential for first responders and emergency medical
personnel to deploy the Hemopurifier(TM) as a treatment against a variety of
currently untreatable biological weapons.
About Aethlon Medical
Aethlon Medical is developing the first medical device to treat infectious
disease. The device, known as the Hemopurifier(TM), is a broad-spectrum
treatment countermeasure against drug and vaccine resistant bioweapons,
naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic
infectious disease targets including Hepatitis-C (HCV) and the Human
Immunodeficiency Virus (HIV). Aethlon has also initiated research on a
second generation Hemopurifier(TM) that targets the capture of growth
factors inherent in the spread of Cancer. More information on Aethlon
Medical and the Hemopurifier(TM) technology can be found at
www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the development
of its planned products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety
of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's
Securities and Exchange Commission filings.
Contact:
Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800 ext. 302
jrichardson@aethlonmedical.com
or
James A. Joyce, 858-459-7800 ext. 301
jj@aethlonmedical.com
Source: Aethlon Medical, Inc.
|
|
